What is Avalo Therapeutics's G&A?

Avalo Therapeutics (AVTX) reported G&A of $6.85M in Q1 2026.

How has Avalo Therapeutics's G&A changed year-over-year?

Avalo Therapeutics's G&A increased by 23.6% year-over-year, from $5.55M to $6.85M.

What is the long-term trend for Avalo Therapeutics's G&A?

Over 3 years (2021 to 2025), Avalo Therapeutics's G&A has grown at a -2.4% compound annual growth rate (CAGR), from $24.66M to $22.9M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Avalo Therapeutics AVTX G&A

G&A at other companies

XencorXNCR

$17.71M+2.1%

AnaptysBio, Inc.ANAB

$26.2M+85.4%

Vera TherapeuticsVERA

$39.12M+146%

ImmunomeIMNM

$12.95M+21.1%

Arcus BiosciencesRCUS

$29M+3.6%

Immunovant, Inc.IMVT

$17.27M-14.4%

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,800%

Enterprise value$929.6M-1,353%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's G&A?: Avalo Therapeutics (AVTX) reported G&A of $6.85M in Q1 2026.
How has Avalo Therapeutics's G&A changed year-over-year?: Avalo Therapeutics's G&A increased by 23.6% year-over-year, from $5.55M to $6.85M.
What is the long-term trend for Avalo Therapeutics's G&A?: Over 3 years (2021 to 2025), Avalo Therapeutics's G&A has grown at a -2.4% compound annual growth rate (CAGR), from $24.66M to $22.9M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.